BC
KRTX

Brookfield Corp’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Brookfield Corp’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,483
Closed -$783K – 771
2022
Q3 		$783K Buy
+3,483
New +$705K ﹤0.01% 556

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brookfield Corp's KRTX Position: Q4 2022 in Review

Brookfield Corp sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2022, closing a stake of 3,483 shares — an estimated $783K sold.

Brookfield Corp first reported a position in KRTX in Q3 2022 and held it in 1 quarter. The position peaked at $783K in Q3 2022. 247 funds tracked by Wall St. Rank hold KRTX as of Q4 2022.

  • Brookfield Corp reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Brookfield Corp sold 3,483 Karuna Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $783K.
  • Brookfield Corp first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Brookfield Corp's Karuna Therapeutics, Inc. Common Stock position peaked at $783K in Q3 2022.
  • 247 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Brookfield Corp's 13F filing for Q4 2022, filed 14 Feb 2023.